 SAN RAFAEL, Calif., July 19, 2021 PRNewswire -- BioMarin Pharmaceutical Inc. NASDAQ: BMRN today announced new data for valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, in its positive pivotal study, GENEr8-1, during an oral presentation at the International Society on Thrombosis and Haemostasis ISTH 2021 Virtual Congress. 